Newsroom.

Fort Lee, NJ - GC Biopharma's GC5107, a new 10% liquid glycine-stabilized IVIG currently pending FDA approval, is manufactured through a unique patented technology. Dr. Alan Huber, Director of Medical Affairs for GC Biopharma USA, and Dr. Gil Bu Kang, General Manager of GC Biopharma's Research and Development Center, will be presenting: "Cation Exchange Chromatography: An Effective Means of Removing FXIa from a 10% IVIG Preparation" at a live clinical symposium at the IgNS Annual Conference being held in Denver, CO from Oct. 5 – 9, 2023.

Factor XIA has been identified as a root cause for increasing the Thrombotic Embolism Events (TEE) rate in patients on IVIG formulations. The clinical symposium will review how GC Biopharma's CEX Chromatography process has additional manufacturing steps and employs a ceramic-based resin to reduce FXIa activity and antigen to below detection limits in GC5107.

GC Biopharma is committed to improving lives while focusing on patient safety. Establishing an effective means of removing FXIa from IVIG preparations has been a long-standing goal for the company. This novel manufacturing process demonstrates GC's commitment to further improve safety for patients who rely on IVIG therapy.

About GC Biopharma USA, Inc.

GC Biopharma USA, Inc., headquartered in Fort Lee, NJ, established its sales, marketing, and business operations in 2018 to serve customers and patients throughout the US. Our foundation is built on our parent company, GC Biopharma's expertise, a leading biopharmaceutical company delivering plasma therapies and vaccines worldwide. With GC Biopharma USA, Inc., GC Biopharma will further extend its footprint, bringing its expertise and legacy to the United States.

About GC Biopharma

GC Biopharma (formerly known as Green Cross Corporation) is a biopharmaceutical company that delivers lifesaving and life-sustaining protein therapeutics and vaccines. Headquartered in Yongin, South Korea, GC Biopharma is one of the world's leading plasma protein and vaccine product manufacturers and has been dedicated to quality healthcare solutions for more than half a century. Green Cross Corporation updated its corporate brand to GC Biopharma in early 2018. Green Cross Corporation remains the Company's legal name.

This press release may contain forward-looking statements that express GC Biopharma's and GC Biopharma USA, Inc.'s management's current beliefs and expectations. Such views do not represent any guarantee by either entity or its government of future performance and involve known and unknown risks, uncertainties, and other factors. GC Biopharma and GC Biopharma USA, Inc. undertake no obligation to update or revise any forward-looking statement contained in this press release or any other forward-looking statements they may make, except as required by law or stock exchange rule.